AKTS | Ticker Profile - Titan Protect

AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology · NMS

$18.87

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-9.17

Based on estimated future earnings — lower means cheaper

Rev Growth

+123.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$33.00

+75% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Aktis Oncology, Inc.

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

https://www.aktisoncology.com

Country: United States Employees: 79 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

-0.029

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0024

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.667

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-21.5%

Historical annualised return based on price data

Max Drawdown

-32.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$29.16

35% below the year high

52W Low

$14.72

28% above the year low

Avg Volume

325,952

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.21

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.29

Heavy leverage — higher financial risk if revenues decline

Current Ratio

19.49

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

19.37

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-703.6%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$8M

Total revenue over the last 12 months

Net Income

$-67,071,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$34.00

Target Median

$33.00

Target Low

$30.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go